Thyrolar25 mcg

Thyrolar is a synthetic thyroid hormone (T4) used for the following indications:

Established / FDA-approved uses

• Hypothyroidism (primary, secondary/pituitary, and tertiary/hypothalamic): Thyrolar is indicated as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis.
• Pituitary TSH suppression: Thyrolar is indicated as an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer, to suppress TSH secretion.

Uses that are NOT appropriate

• Thyrolar is not indicated for treatment of euthyroid goiter or nodular thyroid disease in iodine-sufficient patients, and it is not indicated for suppression of benign thyroid nodules or non-toxic diffuse goiter.
• Thyrolar is not indicated for weight loss; in euthyroid patients, doses within the range of daily hormone requirement are ineffective for weight reduction and larger doses may produce serious or life-threatening toxicity, particularly with concurrent use of sympathomimetic amines.

Each tablet contains Levothyroxine Sodium as the active pharmaceutical ingredient, available in a range of microgram (mcg) strengths (commonly 12.5 mcg to 200 mcg, depending on the brand) to allow precise dose titration. Inactive ingredients vary by manufacturer and typically include fillers, binders, and colorants; patients should avoid switching brands/formulations without physician awareness because bioavailability can differ between products.

Thyrolar is the sodium salt of synthetic levothyroxine (T4), a thyroid hormone chemically and biologically identical to the thyroxine produced naturally by the human thyroid gland. It has a narrow therapeutic index, meaning small differences in dose or absorption can lead to significant clinical effects. Thyrolar is used lifelong in most patients with permanent hypothyroidism and requires periodic laboratory monitoring for safe, effective use.

Thyrolar belongs to the therapeutic class of thyroid hormones, specifically synthetic levothyroxine (T4) preparations used for thyroid hormone replacement and TSH-suppressive therapy.

Levothyroxine Sodium is converted peripherally to triiodothyronine (T3), which binds to thyroid hormone nuclear receptors and regulates gene transcription, thereby controlling metabolic rate, growth, and development in nearly every tissue in the body.

Physiological actions include stimulation of oxygen consumption, body temperature regulation, protein, carbohydrate, and lipid metabolism, and enzyme activity, which together increase basal metabolic rate. Levothyroxine Sodium has a plasma half-life of approximately 6-7 days in euthyroid individuals, and peak clinical effect after starting or changing a dose is typically seen after 4-6 weeks, reflecting the slow equilibration of thyroid hormone stores.

Thyrolar should be taken orally, once daily, on an empty stomach 30-60 minutes before breakfast, at a consistent time each day, and separated by at least 4 hours from calcium, iron, antacids, and other interfering agents (see Dosage and Administration and Interaction).

Thyrolar has a narrow therapeutic index and is subject to clinically significant interactions:

• Absorption-reducing agents: Calcium carbonate, iron/ferrous salts, aluminum- or magnesium-containing antacids, bile acid sequestrants (cholestyramine, colesevelam), sucralfate, and proton pump inhibitors can substantially reduce absorption of Thyrolar; separate dosing by at least 4 hours.
• Enzyme-inducing anticonvulsants/antibiotics: Phenobarbital, phenytoin, carbamazepine, and rifampin can increase hepatic metabolism/clearance of Thyrolar or alter protein binding, potentially increasing dose requirements.
• Warfarin and other oral anticoagulants: Thyrolar can potentiate anticoagulant effect by increasing clotting factor catabolism; monitor coagulation status (INR) closely when starting, stopping, or changing the dose of Thyrolar, and adjust anticoagulant dose as needed.
• Insulin and oral antidiabetic agents: Initiating or increasing the dose of Thyrolar in a diabetic patient may worsen glycemic control and increase requirements for insulin or antidiabetic drugs; monitor blood glucose closely.
• Digoxin: Restoring a hypothyroid patient to euthyroid status with Thyrolar can reduce serum digoxin concentrations and its therapeutic effect; monitor and adjust digoxin dose as needed.
• Estrogens/oral contraceptives: May increase thyroxine-binding globulin, potentially increasing the required dose of Thyrolar; monitor TSH after starting or stopping estrogen therapy.
• Selective serotonin reuptake inhibitors (e.g., sertraline): May reduce the efficacy of Thyrolar, sometimes requiring a dose increase.
• Sympathomimetic amines: Concurrent use with Thyrolar may increase the risk of cardiac adverse effects, particularly in patients being treated for obesity.

Foods and supplements such as soybean-based infant formula, walnuts, high-fiber foods, and grapefruit juice may also reduce absorption of Thyrolar, and coffee taken close to dosing time can reduce absorption as well.

Adverse effects of Thyrolar are generally dose-related and reflect iatrogenic hyperthyroidism from excessive dosing rather than a direct drug toxicity at therapeutic doses:

• Cardiovascular: Palpitations, tachycardia, arrhythmias (including atrial fibrillation, especially in the elderly), angina, increased blood pressure.
• Nervous system: Headache, nervousness, anxiety, insomnia, tremor.
• General/metabolic: Heat intolerance, fever, sweating, weight loss.
• Gastrointestinal: Diarrhea, vomiting, abdominal cramps.
• Musculoskeletal: Muscle weakness, muscle cramps; with long-term overtreatment, reduced bone mineral density.
• Dermatologic: Hair loss (often transient, especially in children in the first months of therapy), flushing.
• Reproductive: Menstrual irregularities.

Most of these effects resolve with dose reduction and represent overtreatment rather than a true idiosyncratic adverse reaction. Rare hypersensitivity reactions (rash, urticaria) can occur, generally related to inactive ingredients rather than the hormone itself.

Pregnancy: Thyrolar is essential for normal fetal neurological development and is not withheld during pregnancy when clinically indicated; treated hypothyroidism should be continued and, in many patients, dose requirements increase during pregnancy (often by 25-50%). TSH should be checked upon confirmation of pregnancy and approximately every 4 weeks through mid-pregnancy, with dose adjusted as needed and dose typically returned to the pre-pregnancy level immediately postpartum, with TSH re-checked 6-8 weeks later. As with any medication in pregnancy, Thyrolar should be used at the lowest effective dose to maintain euthyroidism, and patients should consult their physician for individualized monitoring.

Lactation: Thyrolar is considered compatible with breastfeeding, since it replaces a hormone normally present in breast milk; the amounts excreted in breast milk at properly dosed replacement therapy are not expected to affect the nursing infant. Maintaining maternal euthyroidism is important, and mothers should consult their physician for dose monitoring during lactation.

• Cardiovascular risk in the elderly and those with cardiac disease: Thyrolar can precipitate angina, arrhythmia (including atrial fibrillation), or myocardial infarction if the dose is too high or increased too rapidly; start at a lower dose and titrate slowly with closer monitoring in these patients.
• Adrenal insufficiency: See Contraindications - must be corrected with glucocorticoid replacement before/along with starting Thyrolar to avoid precipitating acute adrenal crisis.
• Do not use for weight loss: Thyrolar is ineffective for weight reduction in euthyroid individuals at replacement doses, and larger doses can cause serious or life-threatening toxicity, especially when combined with sympathomimetic amines used for weight loss.
• Brand/formulation consistency: Because of its narrow therapeutic index, switching brands or formulations of Thyrolar without physician awareness may alter bioavailability and thyroid control; TSH should be re-checked after any product change.
• Bone mineral density: Long-term over-suppression of TSH (excessive dosing) may contribute to reduced bone mineral density, particularly in postmenopausal women.
• Diabetes mellitus: May worsen glycemic control when starting or adjusting Thyrolar; monitor blood glucose closely (see Interaction).
• Myxedema coma: Oral Thyrolar is not appropriate for myxedema coma, a medical emergency requiring intravenous thyroid hormone and supportive care in a hospital setting.
• Pseudotumor cerebri: Has been reported in children receiving Thyrolar therapy, usually within the first months of treatment.

Overdose of Thyrolar produces signs and symptoms of hyperthyroidism, which may be delayed in onset given its long half-life: tachycardia, arrhythmias, chest pain, palpitations, tremor, headache, nervousness, irritability, insomnia, hyperthermia, sweating, heat intolerance, diarrhea, vomiting, menstrual irregularities, and, in severe cases, seizures, cardiac failure, or coma.

If overdose is suspected, seek immediate medical attention or contact emergency services/a poison control center right away. Management is supportive and may include temporarily withholding Thyrolar, monitoring cardiac status, and treating specific symptoms (e.g., beta-blockers for cardiovascular symptoms) under medical supervision; do not attempt to manage a suspected overdose at home without professional guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly

Start Thyrolar at a lower dose (12.5-25 mcg/day) with slower up-titration due to increased risk of cardiac adverse effects (see Precautions and Warnings).

Cardiac disease

Initiate at a reduced dose with close monitoring for angina or arrhythmia (see Precautions and Warnings).

Renal impairment

No well-established specific dose adjustment; individualize based on TSH monitoring.

Hepatic impairment

No well-established specific dose adjustment; individualize based on TSH monitoring.

Pregnancy and lactation

See Pregnancy and Lactation section - dose often needs to be increased during pregnancy, and use is compatible with breastfeeding when properly dosed.

Pediatric patients

See Pediatric Uses section for weight-based dosing by age group.

For most patients with permanent hypothyroidism (e.g., after thyroidectomy, radioiodine ablation, or Hashimoto's thyroiditis), Thyrolar is required lifelong. In some cases of transient or subclinical hypothyroidism, a physician may periodically reassess the ongoing need for therapy. Do not stop Thyrolar without consulting a physician, as abrupt discontinuation can lead to symptomatic hypothyroidism over several weeks given its long half-life.

Thyroid hormones (synthetic levothyroxine/T4 preparations)

Levothyroxine Sodium is converted in peripheral tissues to triiodothyronine (T3), which binds nuclear thyroid hormone receptors to regulate gene transcription, thereby controlling basal metabolic rate, oxygen consumption, thermogenesis, and growth/development across body tissues, replacing the action of endogenous thyroid hormone in deficient patients.

A

Thyrolar is indicated for congenital and acquired hypothyroidism in pediatric patients, including neonates, with dosing weight-based and adjusted by age:

In congenital hypothyroidism, early and adequate treatment with Thyrolar is critical (ideally starting within the first weeks of life) to prevent irreversible neurodevelopmental impairment. Overtreatment in children has been associated with craniosynostosis (infants), pseudotumor cerebri, and premature epiphyseal closure/accelerated bone age with resultant compromised adult height; dosing should be carefully individualized and monitored with periodic TSH/free T4 testing.